Bladder Cancer Treatment Options
Understanding the various bladder cancer treatment options is a crucial step for patients and their families navigating this diagnosis. The approach to treating bladder cancer is highly individualized, depending on factors such as the cancer’s stage, grade, the patient’s overall health, and personal preferences. This article aims to provide a comprehensive overview of the available therapies, from established methods to the latest advancements.
Key Takeaways
- Bladder cancer treatment depends mainly on whether the disease is non-muscle-invasive or muscle-invasive, along with the tumor’s grade and the patient’s overall health.
- For non-muscle-invasive disease, transurethral resection (TURBT) is usually followed by intravesical chemotherapy or, for higher-risk tumors, a course of BCG immunotherapy instilled directly into the bladder.
- Muscle-invasive bladder cancer is generally treated with radical cystectomy and urinary diversion, chemotherapy given before surgery, or radiation combined with chemotherapy for patients who wish to preserve the bladder.
- Newer options such as the antibody-drug conjugate enfortumab vedotin and the targeted drug erdafitinib are expanding treatment for advanced or metastatic urothelial cancer.
- Side effects vary by treatment type, and a multidisciplinary care team helps patients manage them throughout the treatment journey.
Types of Bladder Cancer Treatments
Understanding bladder cancer therapies means recognizing the range of strategies available. The choice of treatment is primarily guided by whether the cancer is non-muscle-invasive (NMIBC) or muscle-invasive (MIBC), and whether it has spread beyond the bladder. A multidisciplinary team — including urologists, oncologists, and radiation oncologists — works together to build the most effective, individualized plan.
Treatment can be local, targeting the cancer within the bladder itself, or systemic, reaching cancer cells throughout the body. The goal is always the same: remove or destroy cancer cells, lower the chance of recurrence, and preserve quality of life. The sections below outline the main categories of bladder cancer treatment.
Surgical Interventions
Surgery remains a cornerstone of bladder cancer treatment, and the surgical approach chosen depends on the tumor’s depth of invasion within the bladder wall. For early-stage, non-muscle-invasive bladder cancer, doctors typically perform Transurethral Resection of Bladder Tumor (TURBT), inserting a cystoscope through the urethra to remove the tumor or burn it away, usually followed by a single dose of chemotherapy instilled directly into the bladder to lower the risk of recurrence.
When the cancer invades the bladder muscle, or when non-muscle-invasive disease is extensive or keeps recurring despite treatment, a cystectomy may be needed. A partial cystectomy removes only the affected portion of the bladder, while a radical cystectomy removes the entire bladder along with nearby lymph nodes and, depending on sex, the prostate and seminal vesicles or the uterus, ovaries, and part of the vagina. When the whole bladder is removed, a urinary diversion procedure creates a new way for urine to leave the body — this may mean routing urine to an external collection bag through an opening in the abdomen (a urostomy), or reconstructing a section of bowel into an internal pouch that allows more normal urination, sometimes called a neobladder.
Systemic and Local Therapies
Beyond surgery, several other types of bladder cancer treatments are available, often combined with surgery or used as the primary approach for more advanced disease. These include chemotherapy, radiation therapy, immunotherapy, and targeted therapy.
- Chemotherapy: These drugs kill cancer cells or stop them from dividing. For non-muscle-invasive bladder cancer, a drug such as mitomycin may be instilled directly into the bladder after TURBT to lower the chance of recurrence. For muscle-invasive or metastatic disease, systemic chemotherapy given intravenously reaches cancer cells throughout the body, often before surgery or alongside radiation.
- Radiation Therapy: This treatment uses high-energy x-rays to destroy cancer cells. It is often combined with chemotherapy for patients who cannot have surgery or who wish to preserve the bladder, and it can also help relieve symptoms in more advanced disease.
- Immunotherapy: This approach helps the body’s own immune system fight cancer. BCG (bacillus Calmette-Guérin), an intravesical immunotherapy, is instilled into the bladder to lower the risk of recurrence and progression in non-muscle-invasive disease at intermediate or high risk; because it can cause more local and systemic side effects than intravesical chemotherapy, it is generally reserved for tumors unlikely to respond to gentler options. For advanced or metastatic disease, checkpoint inhibitors such as pembrolizumab and atezolizumab are given systemically and work by interfering with signals that would otherwise let cancer cells go unrecognized by the immune system.
- Targeted Therapy: These drugs interfere with specific molecules that drive cancer growth. For bladder cancer, this includes erdafitinib, an oral therapy for tumors with certain FGFR gene alterations, and antibody-drug conjugates such as enfortumab vedotin, which deliver a chemotherapy payload directly to cancer cells carrying a specific target protein.
Latest Advancements in Bladder Cancer Treatment
Research has led to newer, FDA-approved options for patients with advanced or metastatic bladder cancer. One recent advance pairs the antibody-drug conjugate enfortumab vedotin with the checkpoint inhibitor pembrolizumab: in a large randomized trial, this combination showed longer survival than standard chemotherapy and is now a first-line option for eligible patients without a contraindication to either drug.
Enfortumab vedotin works by attaching a chemotherapy component to an antibody that targets nectin-4, a protein found on most bladder cancer cells, delivering treatment while limiting damage to healthy tissue. Erdafitinib, the FDA-approved targeted pill mentioned above, is reserved for patients whose FGFR-altered tumor — a change present in roughly one in five metastatic bladder cancers — has continued to grow after chemotherapy.
Additional drug combinations and experimental approaches continue to be studied in clinical trials, giving patients another possible route to newer treatments as this research evolves.
Managing Bladder Cancer Treatment Side Effects
Bladder cancer treatment can cause side effects that affect quality of life, and what a patient experiences depends on the specific treatment used, its duration, and their overall health. Surgery, intravesical therapy, systemic chemotherapy, radiation, and immunotherapy each carry a different pattern of possible effects, from local bladder irritation to more body-wide reactions. Checkpoint inhibitors, for instance, can occasionally trigger immune-related side effects in a minority of patients, since they work by activating the immune system more broadly.
Staying in close touch with the care team — who can adjust supportive medications, coordinate rehabilitation, and bring in nutritional or emotional support when needed — helps patients get through treatment as comfortably as possible. Patients should discuss the specific side effects expected from their own treatment plan with their medical team.
Frequently Asked Questions
What factors determine the best bladder cancer treatment?
The right bladder cancer treatment depends mainly on whether the cancer is non-muscle-invasive or muscle-invasive, its grade, whether it has spread, and the patient’s overall health and preferences. A multidisciplinary team weighs these factors together to build an individualized plan aimed at the most effective outcome with the fewest side effects.
Are there non-surgical bladder cancer treatment options?
Yes. Intravesical chemotherapy or BCG immunotherapy can treat non-muscle-invasive disease without removing the bladder, and systemic chemotherapy, radiation therapy, immunotherapy, or targeted therapy are used for more advanced or metastatic bladder cancer.
How often do I need follow-up after bladder cancer treatment?
Follow-up typically includes periodic cystoscopy and urine tests to check for recurrence, but clinical trials have not defined one standard schedule, so your care team sets the frequency based on your original stage and risk of recurrence. Testing is usually closer together in the first few years and may become less frequent over time if no recurrence is found.
Sources
